Treatment
Best Available Treatment clinical trials
We’re tracking 10 recruiting studies that include Best Available Treatment, each written for real people, not researchers, below.
Recruiting studies
- NCT07124078RecruitingPhase 2
Study of axatilimab for young people with chronic graft-versus-host disease
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
Duarte, CaliforniaAges 2–17 - NCT07623200RecruitingPhase 3
New drug for high-risk essential thrombocythemia with specific genetic mutation
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
Gilbert, ArizonaAges 18 years+ - NCT05832762Recruiting
Clot-buster procedure for blocked neck artery stroke
This trial studies whether an emergency clot-removal procedure through the blood vessels (endovascular treatment) helps people who have a stroke caused by a blocked internal carotid artery in the neck. It compares outcomes in patients treated urgently when imaging shows the blockage is likely the main cause.
Montpellier, FanceAges 18 years+ - NCT07572669RecruitingPhase 2
Moxibustion for Steroid-Resistant Graft-Versus-Host Disease
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
Wuhan, HubeiAges 14–65 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT07016854Recruiting
Early treatment for blocked carotid artery stroke
This trial tests whether early treatment (using a catheter to open the blocked artery) can help people with a stroke caused by a blockage in the internal carotid artery. The goal is to improve recovery and reduce disability.
Hangzhou, ZhejiangAges 18 years+ - NCT04629833RecruitingPhase 3
Mesenchymal cells vs standard care for steroid-resistant graft-versus-host disease
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
AmiensAges 12 years+ - NCT06084819RecruitingPhase 2
New drug combo for relapsed AML
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
Beijing, Beijing MunicipalityAges 14–75 - NCT07089186RecruitingPhase 3
Study of meropenem and pralurbactam for certain antibiotic-resistant infections
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
ShanghaiAges 18–80 - NCT05639647RecruitingPhase 2
Aztreonam plus avibactam for serious gram-negative infections
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
San Diego, CaliforniaAges 9 months–17 years
What Best Available Treatment is being studied for
Conditions with recruiting Best Available Treatment studies.
- Steroid-refractory Acute Graft-versus-host Disease
- Relapsing Multiple Sclerosis
- Gram-Negative Bacterial Infections
- Acute Ischemic Stroke
- Hospital-acquired Bacterial Pneumonia (HABP)
- Ventilator-associated Bacterial Pneumonia (VABP)
- Chronic Graft Versus Host Disease
- Acute Graft Versus Host Disease
- Graft Versus Host Disease
- Allogeneic Hematopoietic Stem Cell Transplantation
Common questions
- Are there clinical trials studying Best Available Treatment?
- Yes. Clin2 currently lists 10 recruiting studies that include Best Available Treatment, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Best Available Treatment trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Best Available Treatment an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Best Available Treatment or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.